136P Tislelizumab (TIS) plus chemotherapy (chemo) for EGFR-mutated non-squamous non-small cell lung cancer (nsq-NSCLC) failed to EGFR tyrosine kinase inhibitors (TKIs) therapies: The primary analysis. (December 2022) - Han, B.; Zhong, H.; Tian, P.; Zhao, Y.; Guo, Q.; Yu, X.; Yu, Z.; Zhang, X.; Li, Y.; Chen, L.; Zhang, Y.; Shi, X.; et al.